Emerging therapeutic targets for idiopathic pulmonary fibrosis: preclinical progress and therapeutic implications. (2nd November 2021)

• Record Type: Journal Article
• Authors: Yanagihara, Toyoshi; Scallan, Ciaran; Ask, Kjetil; Kolb, Martin R. J.
• Is Part Of: Expert opinion on therapeutic targets. Volume 25:Number 11(2021)
• Page Start: 939
• Page End: 948
• Publication Date: 2021-11-02
• Subjects: IPF -- therapy -- novel targets -- biomarker -- idiopathic pulmonary fibrosis; Drugs -- Research -- Periodicals; 615.072
• DOI: 10.1080/14728222.2021.2006186
• Languages: English
• ISSNs: 1744-7631

Abstract

ABSTRACT: Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with high associated morbidity and mortality. The therapeutic landscape has significantly changed in the last 20 years with two drugs currently approved that have demonstrated the ability to slow disease progression. Despite these developments, survival in IPF is limited, so there is a major interest in therapeutic targets which could serve to open up new therapeutic avenues. Areas covered: We review the most recent information regarding drug targets and therapies currently being investigated in preclinical and early-stage clinical trials. Expert opinion: The complex pathogenesis of IPF and variability in disease course and response to therapy highlights the importance of a precision approach to therapy. Novel technologies including transcriptomics and the use of serum biomarkers, will become essential tools to guide future drug development and therapeutic decision making particularly as it pertains to combination therapy.